While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses, …

Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
can transmit more efficiently and partially evade protective immune responses, …

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

Towards the end of 2020, multiple variants of concern (VOCs) and variants of interest (VOIs)
have arisen from the original SARS-CoV-2 Wuhan-Hu-1 strain. Mutations in the Spike …

Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19
pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in …

The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical
trials includes two doses administered three weeks apart. While the decision by some public …

Antibodies that mediate killing of HIV-infected cells through antibody-dependent cellular
cytotoxicity (ADCC) have been implicated in protection from HIV infection and disease …

Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy.
We longitudinally analyze B cell, T cell, and humoral responses to two BNT162b2 mRNA …

The HIV-1 envelope glycoprotein (Env) trimer mediates virus entry into cells. The “closed”
conformation of Env is resistant to nonneutralizing antibodies (nnAbs). These antibodies …